Key Highlights:
- Dr. Reddy’s Laboratories has acquired the trademarks and related assets of the specialty brands Progynova and Cyclo-Progynova in India from Mercury Pharma Group.
- Progynova is an oral hormone replacement therapy used to treat estrogen deficiency symptoms and prevent postmenopausal osteoporosis, while Cyclo-Progynova combines estrogen and progestogen components to manage hormone deficiency symptoms in women.
- The acquisition marks Dr. Reddy’s Laboratories’s entry into the hormone replacement therapy segment and strengthens its gynaecology portfolio in India. According to IQVIA MAT December 2025 data, Progynova leads the estradiol market in India with sales of approximately INR 100 crore.
Implications:
Dr. Reddy’s gains immediate leadership in the estradiol segment, leveraging its physician network to rapidly expand gynecology prescriptions nationwide.
The deal pressures competitors in branded HRT by introducing superior field force penetration and potential line extensions targeting urban menopause care.
Tier-2 city gyno expansion establishes Dr. Reddy’s as a women’s health frontrunner amid rising osteoporosis awareness and screening programs.
Source: Expresspharma | Image: Dr. Reddy
Other Articles
Next
Previous
No Comment! Be the first one.